Biopharma Cred. Regulatory News (BPCR)

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC (the "Company") announces that today it has purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc.

Ordinary Shares:

Date of purchase: 14 July 2020

Number of ordinary shares purchased: 25,000

Lowest price per share: $0.994

Highest price per share: $0.996

Trading venue: London Stock Exchange

Aggregate volume per date per trading venue: 25,000

Weighted average price per day per trading venue: $0.9947

The Company intends to hold the purchased shares in treasury.

Following the above transaction, the Company holds 37,594 of its ordinary shares in treasury and has 1,373,894,473 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,373,894,473. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24